Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†

Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

(2014) Natasha B. Leighl et al.   JOURNAL OF CLINICAL ONCOLOGY

Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer

(2014) Jean-Claude Cutz et al.   Journal of Thoracic Oncology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges

(2012) Corey J. Langer   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Tumour molecular profiling for deciding therapy—the French initiative

(2012) Frédérique Nowak et al.   Nature Reviews Clinical Oncology

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

(2010) Robert Pirker et al.   Journal of Thoracic Oncology

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

(2009) Cesare Gridelli et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE